Orphazyme A/S
Company announcement
No. 17/2017
Major shareholder announcement
Copenhagen, December 18, 2017 – With reference to company announcement no. 5/2017 dated November 16, 2017 regarding the result of the Initial Public Offering (the “Offering”) of Orphazyme A/S (“Orphazyme”) and company announcement no. 10/2017 dated November 16, 2017, Orphazyme hereby announces that it has received the following notification pursuant to section 29 of the Danish Securities Trading Act regarding Novo Holdings A/S’ holding of shares in Orphazyme.
Novo Holdings A/S has increased its direct shareholding in Orphazyme as a consequence of having been redelivered 1,125,000 existing shares in Orphazyme of a nominal value of DKK 1 each previously lent to Carnegie Investment Bank, filial af Carnegie Investment Bank AB (publ), Sverige and Danske Bank A/S (the “Joint Global Coordinators”) for the purposes of delivery of shares to investors as a result of the overallotment option in connection with Orphazyme’s initial public offering of shares.
Accordingly, Novo Holdings A/S’ holding of 3,830,832 shares of a nominal value of DKK 1 each in Orphazyme will correspond to 19.2% of the total share capital and voting rights.
Novo Holdings A/S is a limited liability company organized under the laws of Denmark under CVR no. 24257630 with its registered office at Tuborg Havnevej 19, 2900 Hellerup, Denmark. Novo Holdings A/S is wholly-owned by the Novo Nordisk Foundation.
The Novo Nordisk Foundation is a foundation organised under the laws of Denmark under CVR no. 10582989 with its registered office at Tuborg Havnevej 19, DK-2900 Hellerup, Denmark.
For additional information, please contact
Orphazyme
Anders Vadsholt, CFO +45 28 98 90 55
About Orphazyme A/S
Orphazyme is a Danish biotech company listed on Nasdaq Copenhagen with a late-stage drug pipeline, developing new treatment options for orphan protein-misfolding diseases. The company was founded in 2009 based on early scientific discovery in heat-shock proteins. The company is headquartered in Copenhagen and currently has 30 employees. The lead candidate arimoclomol is in development as a potential treatment for four orphan diseases; two neuromuscular diseases, sporadic Inclusion Body Myositis (“sIBM”) and Amyotrophic Lateral Sclerosis (“ALS”), and two lysosomal storage diseases, Niemann Pick Type C (“NPC”) and Gaucher disease. For more information, please visit www.orphazyme.com.
http://prlibrary-eu.nasdaq.com/Resource/Download/a1b93388-f3cd-4039-b987-2d75376fb01f
